Maker of OxyContin agrees to $270M Oklahoma settlement

Company agreed to settle allegations they helped create the nation’s deadly opioid crisis

The maker of OxyContin and the company’s controlling family agreed Tuesday to pay a groundbreaking $270 million to Oklahoma to settle allegations they helped create the nation’s deadly opioid crisis with their aggressive marketing of the powerful painkiller.

It is the first settlement to come out of the recent coast-to-coast wave of nearly 2,000 lawsuits against Purdue Pharma that threaten to push the company into bankruptcy and have stained the name of the Sackler family, whose members rank among the world’s foremost philanthropists.

“The addiction crisis facing our state and nation is a clear and present danger, but we’re doing something about it today,” Oklahoma Attorney General Mike Hunter said.

Nearly $200 million will go toward establishing a National Center for Addiction Studies and Treatment at Oklahoma State University in Tulsa, while local governments will get $12.5 million. The Sacklers are responsible for $75 million of the settlement.

In settling, the Stamford, Connecticut-based company denied any wrongdoing in connection with what Hunter called “this nightmarish epidemic” and “the worst public health crisis in our state and nation we’ve ever seen.”

The deal comes two months before Oklahoma’s 2017 lawsuit against Purdue Pharma and other drug companies was set to become the first one in the recent barrage of litigation to go to trial. The remaining defendants still face trial May 28.

Opioids, including heroin and prescription drugs such as OxyContin, were a factor in a record 48,000 deaths across the U.S. in 2017, according to the Centers for Disease Control and Prevention. Oklahoma recorded about 400 opioid deaths that year. State officials have said that since 2009, more Oklahomans have died from opioids than in vehicle crashes.

Other states have suffered far worse, including West Virginia, with the nation’s highest opioid death rate. It had over 1,000 deaths in 2017.

In a statement, Purdue Pharma said the money that will go toward addiction studies and treatment in Oklahoma will help people across the country. CEO Craig Landau said the company is committed to “help drive solutions to the opioid addiction crisis.”

READ MORE: Vernon politicians not all happy about possible OD prevention site

Plaintiffs’ attorney Paul Hanly, who is not involved in the Oklahoma case but is representing scores of other governments, welcomed the deal, saying: “That suggests that Purdue is serious about trying to deal with the problem. Hopefully, this is the first of many.”

But some activists were furious , saying they were denied the chance to hold Purdue Pharma fully accountable in public, in front of a jury.

“This decision is a kick in the gut to our community,” said Ryan Hampton, of Los Angeles, who is recovering from opioid addiction. “We deserve to have our day in court with Purdue. The parents, the families, the survivors deserve at least that. And Oklahoma stripped that from us today.”

Purdue Pharma introduced OxyContin in the 1990s and marketed it hard to doctors, making tens of billions of dollars from the drug. But the company has been hit with lawsuits from state and local governments trying to hold it responsible for the scourge of addiction.

The lawsuits accuse the company of downplaying the addiction risks and pushing doctors to increase dosages even as the dangers became known. According to a court filing, Richard Sackler, then senior vice-president responsible for sales, proudly told the audience at a launch party for OxyContin in 1996 that it would create a “blizzard of prescriptions that will bury the competition.”

Earlier this month, Purdue Pharma officials acknowledged that they are considering bankruptcy . But Oklahoma’s attorney general said the company gave assurances it will not take such a step in the near term. And he said the settlement money is “bankruptcy proof” — that is, “it’s not at risk in the event Purdue declares bankruptcy.”

Lance Lang, a 36-year-old recovering user from Oklahoma City, said he is glad some of the settlement will go toward helping those still suffering from addiction.

“My heart breaks for those that we’ve already lost. I’ve buried several myself,” said Lang, who now helps recovering users find housing. “But I also know we have waiting lists of dozens and dozens for our facilities, and the state has waiting lists of hundreds and hundreds of people who need help right now.”

But Cheryl Juaire, whose 23-year-old son Corey died of an overdose in 2011, said she was devastated to hear about the settlement.

Jauire, who lives in Marlborough, Massachusetts, had been organizing a group of hundreds of mothers to go to the first day of the trial and stand outside with photos of their dead children. She said a complete airing of the facts is the only way to fully hold Purdue to account.

A settlement is “a huge disservice to the tens of thousands of families here in the United States who buried a child,” she said. “That’s blood money from our children.”

Members of the Sackler family are defendants in some of the lawsuits but were not actually parties to the Oklahoma case. The company said the family nevertheless voluntarily contributed to the settlement. “We have profound compassion for those who are affected by addiction,” the family said in a statement.

The Sacklers are major donors to cultural institutions, and the family name is emblazoned on the walls at many of the world’s great museums and universities. In the past few weeks, as the accusations have mounted, the Tate museums in London and the Guggenheim Museum in New York have cut ties with the family, and other institutions have come under pressure to turn down donations or remove the Sackler name.

READ MORE: Carfentanil found in 15% of overdose deaths in January: B.C. coroner

A Massachusetts court filing made public earlier this year found that Sackler family members were paid at least $4 billion from 2007 until last year.

Purdue Pharma has settled other lawsuits over the years, and three executives pleaded guilty to criminal charges in 2007. But this is the first settlement to come out of the surge of litigation in the past few years that focuses largely on the company’s more recent conduct.

More than 1,400 federal lawsuits over the opioid crisis have been consolidated in front of a single judge in Cleveland who is pushing the drugmakers and distributors to reach a nationwide settlement.

Sean Murphy And Geoff Mulvihill, The Associated Press

Like us on Facebook and follow us on Twitter.

Just Posted

Affordable housing project sees completion

“We’re pleased we’re going to be starting off with pretty much full occupancy.”

Back in Time

Historical Perspective

Only in Canada, Eh?

Zamboni navigates the roundabout

Shamanic dog training comes to Clearwater

The Shamanic Dog Training Retreat helps owners teach with trust, understanding and freedom

New police force in Surrey must avoid VPD, RCMP errors made in Pickton case: Oppal

Boots are scheduled to be on the ground by spring 2021

Conan turns to the Property Brothers for tips on buying Greenland

Jonathan Scott suggests removing glaciers and mountains to bring in ‘more natural light’

Forests minister visits B.C. town rocked by multiple mill shutdowns

A third of Mackenzie turns out for rally, not much to cheer about

B.C. sockeye returns drop as official calls 2019 ‘extremely challenging’

Federal government says officials are seeing the same thing off Alaska and Washington state

B.C. music teacher accused of sexual misconduct involving girls

Police believe other victims could be out there after the arrest of Lamar Victor Alviar

B.C. family stranded in Croatia desperate to come home

Funds being raised to bring back mom and two children

B.C. man on trial for daughters’ murders says an intruder broke in

Andrew Berry takes stand in his defense for December 2017 deaths of young daughters

‘Plenty of time for a deal’: Teachers’ union expects kids back in school on Sept. 3

BCTF says class size, composition at the heart of the issue

Most Read